This article from Alvarez & Marsal is most popular:
- in North America
Alvarez & Marsal are most popular:
- with readers working within the Aerospace & Defence industries
Market Access is becoming more complex, prompting more pharmaceutical companies to outsource commercialisation services to specialised providers.
Key factors driving this trend include:
- Increasing number of complex, niche, and specialised therapies for smaller patient groups
- Limited public budgets leading to greater competition for fewer resources
- AI integration throughout the drug commercialization process
- Pricing pressures and a global move towards value-based pricing
- Growing number of independent launches by small biopharma companies lacking in-house resources
- Rising demand for outsourced pharma services across the value chain
Combined with a new government that has promised funding stability for continued R&D and a commitment to strengthening underlying infrastructure, sector optimism has increased and the demand for M&A within Market Access services grows ever stronger.
To learn more about the key M&A trends taking shape this year in the Market Access space, read our latest paper.
10 September 2024
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
